 |
| A lab technician at Celltrion tests drug candidates in this file photo. Courtesy of Celltrion |
Celltrion said Wednesday that its net profit jumped 20.1 percent year-on-year last year on the back of robust sales of its biosimilar products in overseas markets.
The South Korean biopharmaceutical firm's net profit came to 623.7 billion won ($521.1 million) last year on a consolidated basis, compared with a profit of 519.2 billion won a year earlier, the company said in a regulatory filing.
Celltrion said its operating profit reached a record high of 753.9 billion won last year, up 5.9 percent; while annual revenue rose 2.3 percent to a record high of 1.89 trillion won.
The company said its biosimilar lineup has maintained a stable presence overseas, noticeably in the United States, citing industry data.
Celltrion said the market share of its Remsima ― a biosimilar copy of Janssen Biotech Inc.'s Remicade ― in the U.S. came to 22.6 percent in the fourth quarter, up 10.8 percentage points from a year earlier.
A corresponding figure for Truxima ― a biosimilar drug based on Rituxan, originally developed by Swiss pharmaceutical giant Roche Holdings ― came to 25.4 percent during the cited quarter, up 5.6 percentage points year-on-year.
Sales of Rekirona, a monoclonal antibody with activity against COVID-19, and COVID-19 self-test kits also contributed to last year's stellar performance, Celltrion said. (Yonhap)
友情鏈接：
